Emcure Pharmaceuticals Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on August 28, 2025
EMCURE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Emcure Pharmaceuticals held its 44th Annual General Meeting on August 28, 2025, via video conferencing, and all 12 resolutions were approved with the requisite majority. Key approvals included the adoption of audited financial statements for FY25, a final dividend of Rs. 3 per equity share (face value Rs. 10), re-appointment of directors Mr. Sunil Mehta and Mr. Samit Mehta, and the appointment of M/s. SYD & Associates as Secretarial Auditors. Shareholders also approved remuneration for executive directors including MD & CEO Satish Mehta (95.20% in favour), Whole-time Directors Sunil Mehta (88.83% in favour), Namita Thapar (98.11%), Samit Mehta (98.01%), and commission for Non-Executive Directors (97.60%). The Sunil Mehta remuneration resolution notably attracted 9.26% invalid votes and 1.91% dissent. The meeting was conducted through remote e-voting and electronic voting during the AGM, overseen by scrutinizer Mehta & Mehta, Company Secretaries.
The final dividend of Rs. 3 per share is a positive cash return for shareholders. While all resolutions passed, the relatively lower approval margins (around 88-95%) on executive remuneration, especially for Sunil Mehta where 9.26% of votes were invalid, signals some shareholder discomfort with promoter/executive pay packages. This is largely a procedural filing with no major surprise.